CLDI - Calidi Biotherapeutics, Inc. Quarterly EPS earnings growth
Calidi Biotherapeutics (CLDI) lacks its own revenue and relies on venture capital. The current quarterly EPS growth value, where the parameter equals 90.60, links price action to fundamental targets. Calidi Biotherapeutics develops allogeneic cell therapies based on stem cells. Future inflows are expected from the commercialization of CLD-101 and CLD-201 systems for tumor destruction.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_CLDI_-_Calidi-Biotherapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Calidi Biotherapeutics, Inc. (CLDI): Quarterly EPS earnings growth from 02/21/2024 to 11/12/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Calidi Biotherapeutics (CLDI)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Debt to Equity Calidi Biotherapeutics|CLDI - Long-Term Debt to Equity|Short-Term Debt to Capital calidibio.com|CLDI - Company Total Debt Obligations|Debts to Book Capitalization Calidi Bio|CLDI - Company Long-Term Indebtedness|Company Short-Term Debts Calidi Biotherapeutics|Quick Liquidity Indicator calidibio.com
- earnings and valuation multiples indicators:
CLDI - Final Profit|Projected Future Earnings Calidi Biotherapeutics|CLDI - Price to Earnings Ratio|Forward P/E Multiple calidibio.com|CLDI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Calidi Bio|CLDI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Calidi Biotherapeutics|CLDI - Earnings per share for the last four quarters|Quarterly EPS earnings growth calidibio.com|CLDI - Earnings per share increase in current year|Earnings growth forecast for next year Calidi Biotherapeutics
Analysis of all company metrics:Calidi Biotherapeutics Inc. - CLDI
The development of oncolytic viruses defines the capital-intensive model of Calidi Biotherapeutics (CLDI), where operational efficiency directly impacts net income. This chart of quarterly earnings per share changes allows for an assessment of EPS dynamics, measuring the real return on each share of capital and identifying the issuer's resilience to shocks, which confirms long-term investor optimism regarding the company's innovative potential.
Key competitors
BeiGene (ONC) - Year-over-year earnings per share growth for the last twelve months|Halozyme Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (RevMed) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Corp AAPG|Quarterly EPS earnings growth CGON|Year-over-year net earnings per share growth for the last 12 months urogen.com URGN|Quarterly EPS earnings growth BCAX (Bicara Therapeutics)|Quarterly EPS earnings growth Personalis Inc PSNL|ERAS - Year-over-year earnings per share growth for the last twelve months|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|AURA - Year-over-year net earnings per share change for the last twelve months|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ARAY (Accuray Inc)|Quarterly EPS earnings growth SLS|Year-over-year net earnings per share change for the last twelve months Actuate Therapeutics Inc|Citius Oncology, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|Protara Therapeutics, Inc. - Quarterly EPS earnings growth|FATE: Year-over-year earnings per share growth for the last twelve months|WHWK: Quarterly EPS earnings growth|TCRX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Champions Oncology Inc|Earnings per share growth in annualized terms for the last twelve months XBiotech USA XBIT|Year-over-year net earnings per share growth for the last 12 months CVM (CEL-SCI Corporation)|Year-over-year earnings per share growth rate for the last twelve months OSTX|Quarterly EPS earnings growth RADX (Radiopharm Theranostics)|Year-over-year earnings per one share growth for the last 12 months ARTV|Adlai Nortye Limited - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months verupharma.com|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|Xilio Therapeutics - Year-over-year earnings per one share growth for the last 12 months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Mural Bio|Year-over-year earnings per share growth for the last twelve months Kairos Pharma Ltd (KAPA)|OKUR: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth GDTC (CytoMed Therapeutics Limited)|Curis Inc. (CRIS) - Earnings per share growth in annualized terms for the last twelve months|APLM: Year-over-year net earnings per share growth for the last 12 months|THAR - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year net earnings per share growth for the last 12 months|GNPX: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma) - Quarterly EPS earnings growth|Xenetic Bio (XBIO) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth SLRX|Year-over-year net earnings per share growth for the last 12 months Kitov Pharma PPBT|Year-over-year earnings per share growth for the last twelve months American Oncology Network, Inc. AONC|Year-over-year net earnings per share change for the last twelve months beigene.com (BGNE)|Checkpoint Therapeutics, Inc. - Quarterly EPS earnings growth|Elevation Oncology Inc. (ELEV) - Year-over-year net earnings per share growth for the last 12 months|icadmed.com (ICAD) - Year-over-year earnings per share growth for the last twelve months|IKNA (Ikena Oncology) - Year-over-year earnings per share growth for the last twelve months|NTBL (Notable Labs, Ltd.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VIRX (Viracta)|Quarterly EPS earnings growth MOR|Year-over-year net earnings per share change for the last twelve months NAYA Biosciences Inc|Quarterly EPS earnings growth AAPGV (Ascentage Pharma Group Ltd)
